Effect of Allopurinol Supplementation on Nitric Oxide Levels in Asphyxiated Newborns

This study aimed to investigate the effect of allopurinol in the management of cerebral hypoxia-ischemia by monitoring nitric oxide levels of serum and cerebrospinal fluid. Sixty asphyxiated infants were divided randomly into two groups. Group I infants (n = 30) received allopurinol (40 mg/kg/day, 3...

Full description

Saved in:
Bibliographic Details
Published inPediatric neurology Vol. 36; no. 1; pp. 17 - 24
Main Authors Gunes, Tamer, MD, Ozturk, Mehmet Adnan, MD, Koklu, Esad, MD, Kose, Kader, MD, Gunes, Isın, MD
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 2007
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This study aimed to investigate the effect of allopurinol in the management of cerebral hypoxia-ischemia by monitoring nitric oxide levels of serum and cerebrospinal fluid. Sixty asphyxiated infants were divided randomly into two groups. Group I infants (n = 30) received allopurinol (40 mg/kg/day, 3 days) within 2 hours after birth. Group II infants (n = 30) received a placebo. Twenty healthy neonates served as control subjects. Cerebrospinal fluid and serum nitric oxide levels were measured within 0-24 hours and 72-96 hours after birth. Both serum and cerebrospinal fluid concentrations of nitric oxide were higher in severely asphyxiated infants (40.86 ± 8.97, 17.3 ± 3.63 μmol/L, respectively) but lower in mildly asphyxiated infants (25.85 ± 3.57, 5.70 ± 2.56 μmol/L, respectively) than in moderately asphyxiated infants (35.86 ± 5.38, 11.06 ± 3.37 μmol/L, respectively) within the first 0-24 hours after birth. Serum nitric oxide levels in control subjects were lower than those of moderately and severely asphyxiated infants. Serum nitric oxide levels of Group I infants within 72-96 hours after birth decreased significantly from their corresponding levels within 0-24 hours after birth. The asphyxiated newborns treated with allopurinol had better neurologic and neurodevelopmental outcome at 12 or more months of age.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ISSN:0887-8994
1873-5150
DOI:10.1016/j.pediatrneurol.2006.08.005